Actelion announces change in its board of directors
Actelion Actelion Ltd announced that Joseph C. Scodari - for personal reasons - has resigned from Actelion's Board of Directors at the beginning of August 2011.
- (1888PressRelease) August 04, 2011 - Robert Cawthorn, Chairman of the Board of Directors at Actelion, commented: "We would like to thank Joe for his dedication to Actelion. We have benefited tremendously from his strategic vision as well as his leadership skills, all based on a long and distinguished career in the healthcare industry."
Robert Cawthorn concluded. "In his efforts on behalf of Actelion, he not only has earned the trust and respect of his fellow board members, but has also been held in high regard by our shareholders: He interacted with many of them, especially in the past few months. We understand his desire to dedicate more time to his personal endeavors and wish him and his family all the best for the future."
Actelion Ltd.
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 2,500 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI).
Contact:
Roland Haefeli
Vice President, Head of Investor Relations & Public Affairs
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
+1 650 624 69 36
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam